Is an injunction available in biosimilar cases under state law?

The US Supreme Court in Sandoz v Amgen remanded the question of whether an injunction is available to Amgen under state unfair competition laws. Natalie Rahhal analyses how the Federal Circuit may rule
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: